Miller, C. R., Chappell, N. P., Leath, C. A., Phippen, N. T., Havrilesky, L. J., & Barnett, J. C. (2015). Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174? In Gynecologic Oncology (Vol. 137, pp. 170–170). Elsevier BV. https://doi.org/10.1016/j.ygyno.2015.01.427

Miller, C. R., N. P. Chappell, C. A. Leath, N. T. Phippen, L. J. Havrilesky, and J. C. Barnett. “Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174?” In Gynecologic Oncology, 137:170–170. Elsevier BV, 2015. https://doi.org/10.1016/j.ygyno.2015.01.427.

Miller CR, Chappell NP, Leath CA, Phippen NT, Havrilesky LJ, Barnett JC. Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174? In: Gynecologic Oncology. Elsevier BV; 2015. p. 170–170.

Miller, C. R., et al. “Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174?” Gynecologic Oncology, vol. 137, Elsevier BV, 2015, pp. 170–170. Crossref, doi:10.1016/j.ygyno.2015.01.427.

Miller CR, Chappell NP, Leath CA, Phippen NT, Havrilesky LJ, Barnett JC. Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174? Gynecologic Oncology. Elsevier BV; 2015. p. 170–170.